>P00125_A01 abituzumab
CAGGTGCAGCTGCAGCAGAGCGGCGGCGAGCTGGCCAAGCCCGGCGCCAGCGTGAAGGTG
AGCTGCAAGGCCAGCGGCTACACCTTCAGCAGCTTCTGGATGCACTGGGTGAGGCAGGCC
CCCGGCCAGGGCCTGGAGTGGATCGGCTACATCAACCCCAGGAGCGGCTACACCGAGTAC
AACGAGATCTTCAGGGACAAGGCCACCATGACCACCGACACCAGCACCAGCACCGCCTAC
ATGGAGCTGAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTACTGCGCCAGCTTCCTG
GGCAGGGGCGCCATGGACTACTGGGGCCAGGGCACCACCGTGACCGTGAGCAGC
>P00125_A02 abrilumab
CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCGCCAGCGTGAAGGTG
AGCTGCAAGGTGAGCGGCTACACCCTGAGCGACCTGAGCATCCACTGGGTGAGGCAGGCC
CCCGGCAAGGGCCTGGAGTGGATGGGCGGCTTCGACCCCCAGGACGGCGAGACCATCTAC
GCCCAGAAGTTCCAGGGCAGGGTGACCATGACCGAGGACACCAGCACCGACACCGCCTAC
ATGGAGCTGAGCAGCCTGAAGAGCGAGGACACCGCCGTGTACTACTGCGCCACCGGCAGC
AGCAGCAGCTGGTTCGACCCCTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
>P00125_A03 adalimumab
GAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCAGGAGCCTGAGGCTG
AGCTGCGCCGCCAGCGGCTTCACCTTCGACGACTACGCCATGCACTGGGTGAGGCAGGCC
CCCGGCAAGGGCCTGGAGTGGGTGAGCGCCATCACCTGGAACAGCGGCCACATCGACTAC
GCCGACAGCGTGGAGGGCAGGTTCACCATCAGCAGGGACAACGCCAAGAACAGCCTGTAC
CTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAAGGTGAGC
TACCTGAGCACCGCCAGCAGCCTGGACTACTGGGGCCAGGGCACCCTGGTGACCGTGAGC
AGC
>P00125_A04 alemtuzumab
CAGGTGCAGCTGCAGGAGAGCGGCCCCGGCCTGGTGAGGCCCAGCCAGACCCTGAGCCTG
ACCTGCACCGTGAGCGGCTTCACCTTCACCGACTTCTACATGAACTGGGTGAGGCAGCCC
CCCGGCAGGGGCCTGGAGTGGATCGGCTTCATCAGGGACAAGGCCAAGGGCTACACCACC
GAGTACAACCCCAGCGTGAAGGGCAGGGTGACCATGCTGGTGGACACCAGCAAGAACCAG
TTCAGCCTGAGGCTGAGCAGCGTGACCGCCGCCGACACCGCCGTGTACTACTGCGCCAGG
GAGGGCCACACCGCCGCCCCCTTCGACTACTGGGGCCAGGGCAGCCTGGTGACCGTGAGC
AGC
>P00125_A05 alirocumab
GAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCTG
AGCTGCGCCGCCAGCGGCTTCACCTTCAACAACTACGCCATGAACTGGGTGAGGCAGGCC
CCCGGCAAGGGCCTGGACTGGGTGAGCACCATCAGCGGCAGCGGCGGCACCACCAACTAC
GCCGACAGCGTGAAGGGCAGGTTCATCATCAGCAGGGACAGCAGCAAGCACACCCTGTAC
CTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAAGGACAGC
AACTGGGGCAACTTCGACCTGTGGGGCAGGGGCACCCTGGTGACCGTGAGCAGC
>P00125_A06 anifrolumab
GAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCGAGAGCCTGAAGATC
AGCTGCAAGGGCAGCGGCTACATCTTCACCAACTACTGGATCGCCTGGGTGAGGCAGATG
CCCGGCAAGGGCCTGGAGAGCATGGGCATCATCTACCCCGGCGACAGCGACATCAGGTAC
AGCCCCAGCTTCCAGGGCCAGGTGACCATCAGCGCCGACAAGAGCATCACCACCGCCTAC
CTGCAGTGGAGCAGCCTGAAGGCCAGCGACACCGCCATGTACTACTGCGCCAGGCACGAC
ATCGAGGGCTTCGACTACTGGGGCAGGGGCACCCTGGTGACCGTGAGCAGC
>P00125_A07 atezolizumab
GAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCTG
AGCTGCGCCGCCAGCGGCTTCACCTTCAGCGACAGCTGGATCCACTGGGTGAGGCAGGCC
CCCGGCAAGGGCCTGGAGTGGGTGGCCTGGATCAGCCCCTACGGCGGCAGCACCTACTAC
GCCGACAGCGTGAAGGGCAGGTTCACCATCAGCGCCGACACCAGCAAGAACACCGCCTAC
CTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAGGAGGCAC
TGGCCCGGCGGCTTCGACTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
>P00125_A08 bapineuzumab
GAGGTGCAGCTGCTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCTG
AGCTGCGCCGCCAGCGGCTTCACCTTCAGCAACTACGGCATGAGCTGGGTGAGGCAGGCC
CCCGGCAAGGGCCTGGAGTGGGTGGCCAGCATCAGGAGCGGCGGCGGCAGGACCTACTAC
AGCGACAACGTGAAGGGCAGGTTCACCATCAGCAGGGACAACAGCAAGAACACCCTGTAC
CTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGTGAGGTACGAC
CACTACAGCGGCAGCAGCGACTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
>P00125_A09 basiliximab
CAGGTGCAGCTGCAGCAGAGCGGCACCGTGCTGGCCAGGCCCGGCGCCAGCGTGAAGATG
AGCTGCAAGGCCAGCGGCTACAGCTTCACCAGGTACTGGATGCACTGGATCAAGCAGAGG
CCCGGCCAGGGCCTGGAGTGGATCGGCGCCATCTACCCCGGCAACAGCGACACCAGCTAC
AACCAGAAGTTCGAGGGCAAGGCCAAGCTGACCGCCGTGACCAGCGCCAGCACCGCCTAC
ATGGAGCTGAGCAGCCTGACCCACGAGGACAGCGCCGTGTACTACTGCAGCAGGGACTAC
GGCTACTACTTCGACTTCTGGGGCCAGGGCACCACCCTGACCGTGAGCAGC
>P00125_A10 bavituximab
GAGGTGCAGCTGCAGCAGAGCGGCCCCGAGCTGGAGAAGCCCGGCGCCAGCGTGAAGCTG
AGCTGCAAGGCCAGCGGCTACAGCTTCACCGGCTACAACATGAACTGGGTGAAGCAGAGC
CACGGCAAGAGCCTGGAGTGGATCGGCCACATCGACCCCTACTACGGCGACACCAGCTAC
AACCAGAAGTTCAGGGGCAAGGCCACCCTGACCGTGGACAAGAGCAGCAGCACCGCCTAC
ATGCAGCTGAAGAGCCTGACCAGCGAGGACAGCGCCGTGTACTACTGCGTGAAGGGCGGC
TACTACGGCCACTGGTACTTCGACGTGTGGGGCGCCGGCACCACCGTGACCGTGAGCAGC
>P00125_A11 belimumab
CAGGTGCAGCTGCAGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCAGCAGCGTGAGGGTG
AGCTGCAAGGCCAGCGGCGGCACCTTCAACAACAACGCCATCAACTGGGTGAGGCAGGCC
CCCGGCCAGGGCCTGGAGTGGATGGGCGGCATCATCCCCATGTTCGGCACCGCCAAGTAC
AGCCAGAACTTCCAGGGCAGGGTGGCCATCACCGCCGACGAGAGCACCGGCACCGCCAGC
ATGGAGCTGAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTACTGCGCCAGGAGCAGG
GACCTGCTGCTGTTCCCCCACCACGCCCTGAGCCCCTGGGGCAGGGGCACCATGGTGACC
GTGAGCAGC
>P00125_A12 benralizumab
GAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCGCCAGCGTGAAGGTG
AGCTGCAAGGCCAGCGGCTACACCTTCACCAGCTACGTGATCCACTGGGTGAGGCAGAGG
CCCGGCCAGGGCCTGGCCTGGATGGGCTACATCAACCCCTACAACGACGGCACCAAGTAC
AACGAGAGGTTCAAGGGCAAGGTGACCATCACCAGCGACAGGAGCACCAGCACCGTGTAC
ATGGAGCTGAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACCTGTGCGGCAGGGAGGGC
ATCAGGTACTACGGCCTGCTGGGCGACTACTGGGGCCAGGGCACCCTGGTGACCGTGAGC
AGC
>P00125_B01 bevacizumab
GAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCTG
AGCTGCGCCGCCAGCGGCTACACCTTCACCAACTACGGCATGAACTGGGTGAGGCAGGCC
CCCGGCAAGGGCCTGGAGTGGGTGGGCTGGATCAACACCTACACCGGCGAGCCCACCTAC
GCCGCCGACTTCAAGAGGAGGTTCACCTTCAGCCTGGACACCAGCAAGAGCACCGCCTAC
CTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAAGTACCCC
CACTACTACGGCAGCAGCCACTGGTACTTCGACGTGTGGGGCCAGGGCACCCTGGTGACC
GTGAGCAGC
>P00125_B02 bimagrumab
CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCGCCAGCGTGAAGGTG
AGCTGCAAGGCCAGCGGCTACACCTTCACCAGCAGCTACATCAACTGGGTGAGGCAGGCC
CCCGGCCAGGGCCTGGAGTGGATGGGCACCATCAACCCCGTGAGCGGCAGCACCAGCTAC
GCCCAGAAGTTCCAGGGCAGGGTGACCATGACCAGGGACACCAGCATCAGCACCGCCTAC
ATGGAGCTGAGCAGGCTGAGGAGCGACGACACCGCCGTGTACTACTGCGCCAGGGGCGGC
TGGTTCGACTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
>P00863_B03 blosozumab
CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCGCCAGCGTGAAGGTG
AGCTGCAAGGTGAGCGGCTTCCCCATCAAGGACACCTTCCAGCACTGGGTGAGGCAGGCC
CCCGGCAAGGGCCTGGAGTGGATGGGCTGGAGCGACCCCGAGATCGGCGACACCGAGTAC
GCCAGCAAGTTCCAGGGCAGGGTGACCATGACCGAGGACACCAGCACCGACACCGCCTAC
ATGGAGCTGAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTACTGCGCCACCGGCGAC
ACCACCTACAAGTTCGACTTCTGGGGCCAGGGCACCACCGTGACCGTGAGCAGC
>P00863_B04 bococizumab
CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCGCCAGCGTGAAGGTG
AGCTGCAAGGCCAGCGGCTACACCTTCACCAGCTACTACATGCACTGGGTGAGGCAGGCC
CCCGGCCAGGGCCTGGAGTGGATGGGCGAGATCAGCCCCTTCGGCGGCAGGACCAACTAC
AACGAGAAGTTCAAGAGCAGGGTGACCATGACCAGGGACACCAGCACCAGCACCGTGTAC
ATGGAGCTGAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTACTGCGCCAGGGAGAGG
CCCCTGTACGCCAGCGACCTGTGGGGCCAGGGCACCACCGTGACCGTGAGCAGC
>P00863_B05 brentuximab
CAGATCCAGCTGCAGCAGAGCGGCCCCGAGGTGGTGAAGCCCGGCGCCAGCGTGAAGATC
AGCTGCAAGGCCAGCGGCTACACCTTCACCGACTACTACATCACCTGGGTGAAGCAGAAG
CCCGGCCAGGGCCTGGAGTGGATCGGCTGGATCTACCCCGGCAGCGGCAACACCAAGTAC
AACGAGAAGTTCAAGGGCAAGGCCACCCTGACCGTGGACACCAGCAGCAGCACCGCCTTC
ATGCAGCTGAGCAGCCTGACCAGCGAGGACACCGCCGTGTACTTCTGCGCCAACTACGGC
AACTACTGGTTCGCCTACTGGGGCCAGGGCACCCAGGTGACCGTGAGCGCC
>P00863_B06 briakinumab
CAGGTGCAGCTGGTGGAGAGCGGCGGCGGCGTGGTGCAGCCCGGCAGGAGCCTGAGGCTG
AGCTGCGCCGCCAGCGGCTTCACCTTCAGCAGCTACGGCATGCACTGGGTGAGGCAGGCC
CCCGGCAAGGGCCTGGAGTGGGTGGCCTTCATCAGGTACGACGGCAGCAACAAGTACTAC
GCCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACAGCAAGAACACCCTGTAC
CTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCAAGACCCACGGC
AGCCACGACAACTGGGGCCAGGGCACCATGGTGACCGTGAGCAGC
>P00863_B07 brodalumab
CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCGCCAGCGTGAAGGTG
AGCTGCAAGGCCAGCGGCTACACCTTCACCAGGTACGGCATCAGCTGGGTGAGGCAGGCC
CCCGGCCAGGGCCTGGAGTGGATGGGCTGGATCAGCACCTACAGCGGCAACACCAACTAC
GCCCAGAAGCTGCAGGGCAGGGTGACCATGACCACCGACACCAGCACCAGCACCGCCTAC
ATGGAGCTGAGGAGCCTGAGGAGCGACGACACCGCCGTGTACTACTGCGCCAGGAGGCAG
CTGTACTTCGACTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
>P00863_B08 canakinumab
CAGGTGCAGCTGGTGGAGAGCGGCGGCGGCGTGGTGCAGCCCGGCAGGAGCCTGAGGCTG
AGCTGCGCCGCCAGCGGCTTCACCTTCAGCGTGTACGGCATGAACTGGGTGAGGCAGGCC
CCCGGCAAGGGCCTGGAGTGGGTGGCCATCATCTGGTACGACGGCGACAACCAGTACTAC
GCCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACAGCAAGAACACCCTGTAC
CTGCAGATGAACGGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAGGGACCTG
AGGACCGGCCCCTTCGACTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
>P00863_B09 carlumab
CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCAGCAGCGTGAAGGTG
AGCTGCAAGGCCAGCGGCGGCACCTTCAGCAGCTACGGCATCAGCTGGGTGAGGCAGGCC
CCCGGCCAGGGCCTGGAGTGGATGGGCGGCATCATCCCCATCTTCGGCACCGCCAACTAC
GCCCAGAAGTTCCAGGGCAGGGTGACCATCACCGCCGACGAGAGCACCAGCACCGCCTAC
ATGGAGCTGAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTACTGCGCCAGGTACGAC
GGCATCTACGGCGAGCTGGACTTCTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
>P00863_B10 certolizumab
GAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCTG
AGCTGCGCCGCCAGCGGCTACGTGTTCACCGACTACGGCATGAACTGGGTGAGGCAGGCC
CCCGGCAAGGGCCTGGAGTGGATGGGCTGGATCAACACCTACATCGGCGAGCCCATCTAC
GCCGACAGCGTGAAGGGCAGGTTCACCTTCAGCCTGGACACCAGCAAGAGCACCGCCTAC
CTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAGGGGCTAC
AGGAGCTACGCCATGGACTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
>P00863_B11 cetuximab
CAGGTGCAGCTGAAGCAGAGCGGCCCCGGCCTGGTGCAGCCCAGCCAGAGCCTGAGCATC
ACCTGCACCGTGAGCGGCTTCAGCCTGACCAACTACGGCGTGCACTGGGTGAGGCAGAGC
CCCGGCAAGGGCCTGGAGTGGCTGGGCGTGATCTGGAGCGGCGGCAACACCGACTACAAC
ACCCCCTTCACCAGCAGGCTGAGCATCAACAAGGACAACAGCAAGAGCCAGGTGTTCTTC
AAGATGAACAGCCTGCAGAGCAACGACACCGCCATCTACTACTGCGCCAGGGCCCTGACC
TACTACGACTACGAGTTCGCCTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCGCC
>P00863_B12 cixutumumab
GAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCAGCAGCGTGAAGGTG
AGCTGCAAGGCCAGCGGCGGCACCTTCAGCAGCTACGCCATCAGCTGGGTGAGGCAGGCC
CCCGGCCAGGGCCTGGAGTGGATGGGCGGCATCATCCCCATCTTCGGCACCGCCAACTAC
GCCCAGAAGTTCCAGGGCAGGGTGACCATCACCGCCGACAAGAGCACCAGCACCGCCTAC
ATGGAGCTGAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTACTGCGCCAGGGCCCCC
CTGAGGTTCCTGGAGTGGAGCACCCAGGACCACTACTACTACTACTACATGGACGTGTGG
GGCAAGGGCACCACCGTGACCGTGAGCAGC
>P00863_C01 clazakizumab
GAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCTG
AGCTGCGCCGCCAGCGGCTTCAGCCTGAGCAACTACTACGTGACCTGGGTGAGGCAGGCC
CCCGGCAAGGGCCTGGAGTGGGTGGGCATCATCTACGGCAGCGACGAGACCGCCTACGCC
ACCAGCGCCATCGGCAGGTTCACCATCAGCAGGGACAACAGCAAGAACACCCTGTACCTG
CAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAGGGACGACAGC
AGCGACTGGGACGCCAAGTTCAACCTGTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
>P00863_C02 codrituzumab
CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCGCCAGCGTGAAGGTG
AGCTGCAAGGCCAGCGGCTACACCTTCACCGACTACGAGATGCACTGGGTGAGGCAGGCC
CCCGGCCAGGGCCTGGAGTGGATGGGCGCCCTGGACCCCAAGACCGGCGACACCGCCTAC
AGCCAGAAGTTCAAGGGCAGGGTGACCCTGACCGCCGACAAGAGCACCAGCACCGCCTAC
ATGGAGCTGAGCAGCCTGACCAGCGAGGACACCGCCGTGTACTACTGCACCAGGTTCTAC
AGCTACACCTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
>P00863_C03 crenezumab
GAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCTG
AGCTGCGCCGCCAGCGGCTTCACCTTCAGCAGCTACGGCATGAGCTGGGTGAGGCAGGCC
CCCGGCAAGGGCCTGGAGCTGGTGGCCAGCATCAACAGCAACGGCGGCAGCACCTACTAC
CCCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACGCCAAGAACAGCCTGTAC
CTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAGCGGCGAC
TACTGGGGCCAGGGCACCACCGTGACCGTGAGCAGC
>P00863_C04 dacetuzumab
GAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCTG
AGCTGCGCCGCCAGCGGCTACAGCTTCACCGGCTACTACATCCACTGGGTGAGGCAGGCC
CCCGGCAAGGGCCTGGAGTGGGTGGCCAGGGTGATCCCCAACGCCGGCGGCACCAGCTAC
AACCAGAAGTTCAAGGGCAGGTTCACCCTGAGCGTGGACAACAGCAAGAACACCGCCTAC
CTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAGGGAGGGC
ATCTACTGGTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
>P00863_C05 daclizumab
CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCAGCAGCGTGAAGGTG
AGCTGCAAGGCCAGCGGCTACACCTTCACCAGCTACAGGATGCACTGGGTGAGGCAGGCC
CCCGGCCAGGGCCTGGAGTGGATCGGCTACATCAACCCCAGCACCGGCTACACCGAGTAC
AACCAGAAGTTCAAGGACAAGGCCACCATCACCGCCGACGAGAGCACCAACACCGCCTAC
ATGGAGCTGAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTACTGCGCCAGGGGCGGC
GGCGTGTTCGACTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
>P00863_C06 dalotuzumab
CAGGTGCAGCTGCAGGAGAGCGGCCCCGGCCTGGTGAAGCCCAGCGAGACCCTGAGCCTG
ACCTGCACCGTGAGCGGCTACAGCATCACCGGCGGCTACCTGTGGAACTGGATCAGGCAG
CCCCCCGGCAAGGGCCTGGAGTGGATCGGCTACATCAGCTACGACGGCACCAACAACTAC
AAGCCCAGCCTGAAGGACAGGGTGACCATCAGCAGGGACACCAGCAAGAACCAGTTCAGC
CTGAAGCTGAGCAGCGTGACCGCCGCCGACACCGCCGTGTACTACTGCGCCAGGTACGGC
AGGGTGTTCTTCGACTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
>P00863_C07 daratumumab
GAGGTGCAGCTGCTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCTG
AGCTGCGCCGTGAGCGGCTTCACCTTCAACAGCTTCGCCATGAGCTGGGTGAGGCAGGCC
CCCGGCAAGGGCCTGGAGTGGGTGAGCGCCATCAGCGGCAGCGGCGGCGGCACCTACTAC
GCCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACAGCAAGAACACCCTGTAC
CTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTTCTGCGCCAAGGACAAG
ATCCTGTGGTTCGGCGAGCCCGTGTTCGACTACTGGGGCCAGGGCACCCTGGTGACCGTG
AGCAGC
>P00863_C08 denosumab
GAGGTGCAGCTGCTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCTG
AGCTGCGCCGCCAGCGGCTTCACCTTCAGCAGCTACGCCATGAGCTGGGTGAGGCAGGCC
CCCGGCAAGGGCCTGGAGTGGGTGAGCGGCATCACCGGCAGCGGCGGCAGCACCTACTAC
GCCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACAGCAAGAACACCCTGTAC
CTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAAGGACCCC
GGCACCACCGTGATCATGAGCTGGTTCGACCCCTGGGGCCAGGGCACCCTGGTGACCGTG
AGCAGC
>P00863_C09 dinutuximab
GAGGTGCAGCTGCTGCAGAGCGGCCCCGAGCTGGAGAAGCCCGGCGCCAGCGTGATGATC
AGCTGCAAGGCCAGCGGCAGCAGCTTCACCGGCTACAACATGAACTGGGTGAGGCAGAAC
ATCGGCAAGAGCCTGGAGTGGATCGGCGCCATCGACCCCTACTACGGCGGCACCAGCTAC
AACCAGAAGTTCAAGGGCAGGGCCACCCTGACCGTGGACAAGAGCAGCAGCACCGCCTAC
ATGCACCTGAAGAGCCTGACCAGCGAGGACAGCGCCGTGTACTACTGCGTGAGCGGCATG
GAGTACTGGGGCCAGGGCACCAGCGTGACCGTGAGCAGC
>P00863_C10 drozitumab
GAGGTGCAGCTGGTGCAGAGCGGCGGCGGCGTGGAGAGGCCCGGCGGCAGCCTGAGGCTG
AGCTGCGCCGCCAGCGGCTTCACCTTCGACGACTACGCCATGAGCTGGGTGAGGCAGGCC
CCCGGCAAGGGCCTGGAGTGGGTGAGCGGCATCAACTGGCAGGGCGGCAGCACCGGCTAC
GCCGACAGCGTGAAGGGCAGGGTGACCATCAGCAGGGACAACGCCAAGAACAGCCTGTAC
CTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAAGATCCTG
GGCGCCGGCAGGGGCTGGTACTTCGACTACTGGGGCAAGGGCACCACCGTGACCGTGAGC
AGC
>P00863_C11 duligotuzumab
GAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCTG
AGCTGCGCCGCCAGCGGCTTCACCCTGAGCGGCGACTGGATCCACTGGGTGAGGCAGGCC
CCCGGCAAGGGCCTGGAGTGGGTGGGCGAGATCAGCGCCGCCGGCGGCTACACCGACTAC
GCCGACAGCGTGAAGGGCAGGTTCACCATCAGCGCCGACACCAGCAAGAACACCGCCTAC
CTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAGGGAGAGC
AGGGTGAGCTTCGAGGCCGCCATGGACTACTGGGGCCAGGGCACCCTGGTGACCGTGAGC
AGC
>P00863_C12 dupilumab
GAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGAGCAGCCCGGCGGCAGCCTGAGGCTG
AGCTGCGCCGGCAGCGGCTTCACCTTCAGGGACTACGCCATGACCTGGGTGAGGCAGGCC
CCCGGCAAGGGCCTGGAGTGGGTGAGCAGCATCAGCGGCAGCGGCGGCAACACCTACTAC
GCCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACAGCAAGAACACCCTGTAC
CTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAAGGACAGG
CTGAGCATCACCATCAGGCCCAGGTACTACGGCCTGGACGTGTGGGGCCAGGGCACCACC
GTGACCGTGAGCAGC
>P00863_D01 eculizumab
CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCGCCAGCGTGAAGGTG
AGCTGCAAGGCCAGCGGCTACATCTTCAGCAACTACTGGATCCAGTGGGTGAGGCAGGCC
CCCGGCCAGGGCCTGGAGTGGATGGGCGAGATCCTGCCCGGCAGCGGCAGCACCGAGTAC
ACCGAGAACTTCAAGGACAGGGTGACCATGACCAGGGACACCAGCACCAGCACCGTGTAC
ATGGAGCTGAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTACTGCGCCAGGTACTTC
TTCGGCAGCAGCCCCAACTGGTACTTCGACGTGTGGGGCCAGGGCACCCTGGTGACCGTG
AGCAGC
>P00863_D02 efalizumab
GAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCTG
AGCTGCGCCGCCAGCGGCTACAGCTTCACCGGCCACTGGATGAACTGGGTGAGGCAGGCC
CCCGGCAAGGGCCTGGAGTGGGTGGGCATGATCCACCCCAGCGACAGCGAGACCAGGTAC
AACCAGAAGTTCAAGGACAGGTTCACCATCAGCGTGGACAAGAGCAAGAACACCCTGTAC
CTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAGGGGCATC
TACTTCTACGGCACCACCTACTTCGACTACTGGGGCCAGGGCACCCTGGTGACCGTGAGC
AGC
>P01274_D03 eldelumab
CAGATGCAGCTGGTGGAGAGCGGCGGCGGCGTGGTGCAGCCCGGCAGGAGCCTGAGGCTG
AGCTGCACCGCCAGCGGCTTCACCTTCAGCAACAACGGCATGCACTGGGTGAGGCAGGCC
CCCGGCAAGGGCCTGGAGTGGGTGGCCGTGATCTGGTTCGACGGCATGAACAAGTTCTAC
GTGGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACAGCAAGAACACCCTGTAC
CTGGAGATGAACAGCCTGAGGGCCGAGGACACCGCCATCTACTACTGCGCCAGGGAGGGC
GACGGCAGCGGCATCTACTACTACTACGGCATGGACGTGTGGGGCCAGGGCACCACCGTG
ACCGTGAGCAGC
>P01274_D04 elotuzumab
GAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCTG
AGCTGCGCCGCCAGCGGCTTCGACTTCAGCAGGTACTGGATGAGCTGGGTGAGGCAGGCC
CCCGGCAAGGGCCTGGAGTGGATCGGCGAGATCAACCCCGACAGCAGCACCATCAACTAC
GCCCCCAGCCTGAAGGACAAGTTCATCATCAGCAGGGACAACGCCAAGAACAGCCTGTAC
CTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAGGCCCGAC
GGCAACTACTGGTACTTCGACGTGTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
>P01274_D05 emibetuzumab
CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCGCCAGCGTGAAGGTG
AGCTGCAAGGCCAGCGGCTACACCTTCACCGACTACTACATGCACTGGGTGAGGCAGGCC
CCCGGCCAGGGCCTGGAGTGGATGGGCAGGGTGAACCCCAACAGGAGGGGCACCACCTAC
AACCAGAAGTTCGAGGGCAGGGTGACCATGACCACCGACACCAGCACCAGCACCGCCTAC
ATGGAGCTGAGGAGCCTGAGGAGCGACGACACCGCCGTGTACTACTGCGCCAGGGCCAAC
TGGCTGGACTACTGGGGCCAGGGCACCACCGTGACCGTGAGCAGC
>P01274_D06 enokizumab
CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCAGCAGCGTGAAGGTG
AGCTGCAAGGCCAGCGGCGGCACCTTCAGCTACTACTGGATCGAGTGGGTGAGGCAGGCC
CCCGGCCAGGGCCTGGAGTGGATGGGCGAGATCCTGCCCGGCAGCGGCACCACCAACCCC
AACGAGAAGTTCAAGGGCAGGGTGACCATCACCGCCGACGAGAGCACCAGCACCGCCTAC
ATGGAGCTGAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTACTGCGCCAGGGCCGAC
TACTACGGCAGCGACTACGTGAAGTTCGACTACTGGGGCCAGGGCACCCTGGTGACCGTG
AGCAGC
>P01274_D07 epratuzumab
CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCAGCAGCGTGAAGGTG
AGCTGCAAGGCCAGCGGCTACACCTTCACCAGCTACTGGCTGCACTGGGTGAGGCAGGCC
CCCGGCCAGGGCCTGGAGTGGATCGGCTACATCAACCCCAGGAACGACTACACCGAGTAC
AACCAGAACTTCAAGGACAAGGCCACCATCACCGCCGACGAGAGCACCAACACCGCCTAC
ATGGAGCTGAGCAGCCTGAGGAGCGAGGACACCGCCTTCTACTTCTGCGCCAGGAGGGAC
ATCACCACCTTCTACTGGGGCCAGGGCACCACCGTGACCGTGAGCAGC
>P01274_D08 etrolizumab
GAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCTG
AGCTGCGCCGCCAGCGGCTTCTTCATCACCAACAACTACTGGGGCTGGGTGAGGCAGGCC
CCCGGCAAGGGCCTGGAGTGGGTGGGCTACATCAGCTACAGCGGCAGCACCAGCTACAAC
CCCAGCCTGAAGAGCAGGTTCACCATCAGCAGGGACACCAGCAAGAACACCTTCTACCTG
CAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAGGACCGGCAGC
AGCGGCTACTTCGACTTCTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
>P01274_D09 evolocumab
GAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCGCCAGCGTGAAGGTG
AGCTGCAAGGCCAGCGGCTACACCCTGACCAGCTACGGCATCAGCTGGGTGAGGCAGGCC
CCCGGCCAGGGCCTGGAGTGGATGGGCTGGGTGAGCTTCTACAACGGCAACACCAACTAC
GCCCAGAAGCTGCAGGGCAGGGGCACCATGACCACCGACCCCAGCACCAGCACCGCCTAC
ATGGAGCTGAGGAGCCTGAGGAGCGACGACACCGCCGTGTACTACTGCGCCAGGGGCTAC
GGCATGGACGTGTGGGGCCAGGGCACCACCGTGACCGTGAGCAGC
>P01274_D10 farletuzumab
GAGGTGCAGCTGGTGGAGAGCGGCGGCGGCGTGGTGCAGCCCGGCAGGAGCCTGAGGCTG
AGCTGCAGCGCCAGCGGCTTCACCTTCAGCGGCTACGGCCTGAGCTGGGTGAGGCAGGCC
CCCGGCAAGGGCCTGGAGTGGGTGGCCATGATCAGCAGCGGCGGCAGCTACACCTACTAC
GCCGACAGCGTGAAGGGCAGGTTCGCCATCAGCAGGGACAACGCCAAGAACACCCTGTTC
CTGCAGATGGACAGCCTGAGGCCCGAGGACACCGGCGTGTACTTCTGCGCCAGGCACGGC
GACGACCCCGCCTGGTTCGCCTACTGGGGCCAGGGCACCCCCGTGACCGTGAGCAGC
>P01274_D11 fasinumab
CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCGCCAGCGTGAAGGTG
AGCTGCAAGGTGAGCGGCTTCACCCTGACCGAGCTGAGCATCCACTGGGTGAGGCAGGCC
CCCGGCAAGGGCCTGGAGTGGATGGGCGGCTTCGACCCCGAGGACGGCGAGACCATCTAC
GCCCAGAAGTTCCAGGGCAGGGTGACCATGACCGAGGACACCAGCACCGACACCGCCTAC
ATGGAGCTGACCAGCCTGAGGAGCGAGGACACCGCCGTGTACTACTGCAGCACCATCTTC
GGCGTGGTGACCAACTTCGACAACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
>P01274_D12 fezakinumab
CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCGCCAGCGTGAAGGTG
AGCTGCAAGGCCAGCGGCTACACCTTCACCAACTACTACATGCACTGGGTGAGGCAGGCC
CCCGGCCAGGGCCTGGAGTGGGTGGGCTGGATCAACCCCTACACCGGCAGCGCCTTCTAC
GCCCAGAAGTTCAGGGGCAGGGTGACCATGACCAGGGACACCAGCATCAGCACCGCCTAC
ATGGAGCTGAGCAGGCTGAGGAGCGACGACACCGCCGTGTACTACTGCGCCAGGGAGCCC
GAGAAGTTCGACAGCGACGACAGCGACGTGTGGGGCAGGGGCACCCTGGTGACCGTGAGC
AGC
>P01274_E01 ficlatuzumab
CAGGTGCAGCTGGTGCAGCCCGGCGCCGAGGTGAAGAAGCCCGGCACCAGCGTGAAGCTG
AGCTGCAAGGCCAGCGGCTACACCTTCACCACCTACTGGATGCACTGGGTGAGGCAGGCC
CCCGGCCAGGGCCTGGAGTGGATCGGCGAGATCAACCCCACCAACGGCCACACCAACTAC
AACCAGAAGTTCCAGGGCAGGGCCACCCTGACCGTGGACAAGAGCACCAGCACCGCCTAC
ATGGAGCTGAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTACTGCGCCAGGAACTAC
GTGGGCAGCATCTTCGACTACTGGGGCCAGGGCACCCTGCTGACCGTGAGCAGC
>P01274_E02 figitumumab
GAGGTGCAGCTGCTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCTG
AGCTGCACCGCCAGCGGCTTCACCTTCAGCAGCTACGCCATGAACTGGGTGAGGCAGGCC
CCCGGCAAGGGCCTGGAGTGGGTGAGCGCCATCAGCGGCAGCGGCGGCACCACCTTCTAC
GCCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACAGCAGGACCACCCTGTAC
CTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAAGGACCTG
GGCTGGAGCGACAGCTACTACTACTACTACGGCATGGACGTGTGGGGCCAGGGCACCACC
GTGACCGTGAGCAGC
>P01274_E03 fletikumab
CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAGGCCCGGCGCCAGCGTGAAGGTG
AGCTGCAAGGCCAGCGGCTACACCTTCACCAACGACATCATCCACTGGGTGAGGCAGGCC
CCCGGCCAGAGGCTGGAGTGGATGGGCTGGATCAACGCCGGCTACGGCAACACCCAGTAC
AGCCAGAACTTCCAGGACAGGGTGAGCATCACCAGGGACACCAGCGCCAGCACCGCCTAC
ATGGAGCTGATCAGCCTGAGGAGCGAGGACACCGCCGTGTACTACTGCGCCAGGGAGCCC
CTGTGGTTCGGCGAGAGCAGCCCCCACGACTACTACGGCATGGACGTGTGGGGCCAGGGC
ACCACCGTGACCGTGAGCAGC
>P01274_E04 foralumab
CAGGTGCAGCTGGTGGAGAGCGGCGGCGGCGTGGTGCAGCCCGGCAGGAGCCTGAGGCTG
AGCTGCGCCGCCAGCGGCTTCAAGTTCAGCGGCTACGGCATGCACTGGGTGAGGCAGGCC
CCCGGCAAGGGCCTGGAGTGGGTGGCCGTGATCTGGTACGACGGCAGCAAGAAGTACTAC
GTGGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACAGCAAGAACACCCTGTAC
CTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAGGCAGATG
GGCTACTGGCACTTCGACCTGTGGGGCAGGGGCACCCTGGTGACCGTGAGCAGC
>P01274_E05 fresolimumab
CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCAGCAGCGTGAAGGTG
AGCTGCAAGGCCAGCGGCTACACCTTCAGCAGCAACGTGATCAGCTGGGTGAGGCAGGCC
CCCGGCCAGGGCCTGGAGTGGATGGGCGGCGTGATCCCCATCGTGGACATCGCCAACTAC
GCCCAGAGGTTCAAGGGCAGGGTGACCATCACCGCCGACGAGAGCACCAGCACCACCTAC
ATGGAGCTGAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTACTGCGCCAGCACCCTG
GGCCTGGTGCTGGACGCCATGGACTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
>P01274_E06 fulranumab
GAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCTG
AGCTGCGCCGCCAGCGGCTTCACCCTGAGGAGCTACAGCATGAACTGGGTGAGGCAGGCC
CCCGGCAAGGGCCTGGAGTGGGTGAGCTACATCAGCAGGAGCAGCCACACCATCTTCTAC
GCCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACGCCAAGAACAGCCTGTAC
CTGCAGATGGACAGCCTGAGGGACGAGGACACCGCCATGTACTACTGCGCCAGGGTGTAC
AGCAGCGGCTGGCACGTGAGCGACTACTTCGACTACTGGGGCCAGGGCATCCTGGTGACC
GTGAGCAGC
>P01274_E07 galiximab
CAGGTGCAGCTGCAGGAGAGCGGCCCCGGCCTGGTGAAGCCCAGCGAGACCCTGAGCCTG
ACCTGCGCCGTGAGCGGCGGCAGCATCAGCGGCGGCTACGGCTGGGGCTGGATCAGGCAG
CCCCCCGGCAAGGGCCTGGAGTGGATCGGCAGCTTCTACAGCAGCAGCGGCAACACCTAC
TACAACCCCAGCCTGAAGAGCCAGGTGACCATCAGCACCGACACCAGCAAGAACCAGTTC
AGCCTGAAGCTGAACAGCATGACCGCCGCCGACACCGCCGTGTACTACTGCGTGAGGGAC
AGGCTGTTCAGCGTGGTGGGCATGGTGTACAACAACTGGTTCGACGTGTGGGGCCCCGGC
GTGCTGGTGACCGTGAGCAGC
>P01274_E08 ganitumab
CAGGTGCAGCTGCAGGAGAGCGGCCCCGGCCTGGTGAAGCCCAGCGGCACCCTGAGCCTG
ACCTGCGCCGTGAGCGGCGGCAGCATCAGCAGCAGCAACTGGTGGAGCTGGGTGAGGCAG
CCCCCCGGCAAGGGCCTGGAGTGGATCGGCGAGATCTACCACAGCGGCAGCACCAACTAC
AACCCCAGCCTGAAGAGCAGGGTGACCATCAGCGTGGACAAGAGCAAGAACCAGTTCAGC
CTGAAGCTGAGCAGCGTGACCGCCGCCGACACCGCCGTGTACTACTGCGCCAGGTGGACC
GGCAGGACCGACGCCTTCGACATCTGGGGCCAGGGCACCATGGTGACCGTGAGCAGC
>P01274_E09 gantenerumab
CAGGTGGAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCTG
AGCTGCGCCGCCAGCGGCTTCACCTTCAGCAGCTACGCCATGAGCTGGGTGAGGCAGGCC
CCCGGCAAGGGCCTGGAGTGGGTGAGCGCCATCAACGCCAGCGGCACCAGGACCTACTAC
GCCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACAGCAAGAACACCCTGTAC
CTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAGGGGCAAG
GGCAACACCCACAAGCCCTACGGCTACGTGAGGTACTTCGACGTGTGGGGCCAGGGCACC
CTGGTGACCGTGAGCAGC
>P01274_E10 gemtuzumab
GAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCAGCAGCGTGAAGGTG
AGCTGCAAGGCCAGCGGCTACACCATCACCGACAGCAACATCCACTGGGTGAGGCAGGCC
CCCGGCCAGAGCCTGGAGTGGATCGGCTACATCTACCCCTACAACGGCGGCACCGACTAC
AACCAGAAGTTCAAGAACAGGGCCACCCTGACCGTGGACAACCCCACCAACACCGCCTAC
ATGGAGCTGAGCAGCCTGAGGAGCGAGGACACCGCCTTCTACTACTGCGTGAACGGCAAC
CCCTGGCTGGCCTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
>P01274_E11 gevokizumab
CAGGTGCAGCTGCAGGAGAGCGGCCCCGGCCTGGTGAAGCCCAGCCAGACCCTGAGCCTG
ACCTGCAGCTTCAGCGGCTTCAGCCTGAGCACCAGCGGCATGGGCGTGGGCTGGATCAGG
CAGCCCAGCGGCAAGGGCCTGGAGTGGCTGGCCCACATCTGGTGGGACGGCGACGAGAGC
TACAACCCCAGCCTGAAGAGCAGGCTGACCATCAGCAAGGACACCAGCAAGAACCAGGTG
AGCCTGAAGATCACCAGCGTGACCGCCGCCGACACCGCCGTGTACTTCTGCGCCAGGAAC
AGGTACGACCCCCCCTGGTTCGTGGACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
>P01274_E12 girentuximab
GACGTGAAGCTGGTGGAGAGCGGCGGCGGCCTGGTGAAGCTGGGCGGCAGCCTGAAGCTG
AGCTGCGCCGCCAGCGGCTTCACCTTCAGCAACTACTACATGAGCTGGGTGAGGCAGACC
CCCGAGAAGAGGCTGGAGCTGGTGGCCGCCATCAACAGCGACGGCGGCATCACCTACTAC
CTGGACACCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACGCCAAGAACACCCTGTAC
CTGCAGATGAGCAGCCTGAAGAGCGAGGACACCGCCCTGTTCTACTGCGCCAGGCACAGG
AGCGGCTACTTCAGCATGGACTACTGGGGCCAGGGCACCAGCGTGACCGTGAGCAGC
>P01274_F01 glembatumumab
CAGGTGCAGCTGCAGGAGAGCGGCCCCGGCCTGGTGAAGCCCAGCCAGACCCTGAGCCTG
ACCTGCACCGTGAGCGGCGGCAGCATCAGCAGCTTCAACTACTACTGGAGCTGGATCAGG
CACCACCCCGGCAAGGGCCTGGAGTGGATCGGCTACATCTACTACAGCGGCAGCACCTAC
AGCAACCCCAGCCTGAAGAGCAGGGTGACCATCAGCGTGGACACCAGCAAGAACCAGTTC
AGCCTGACCCTGAGCAGCGTGACCGCCGCCGACACCGCCGTGTACTACTGCGCCAGGGGC
TACAACTGGAACTACTTCGACTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
>P01274_F02 golimumab
CAGGTGCAGCTGGTGGAGAGCGGCGGCGGCGTGGTGCAGCCCGGCAGGAGCCTGAGGCTG
AGCTGCGCCGCCAGCGGCTTCATCTTCAGCAGCTACGCCATGCACTGGGTGAGGCAGGCC
CCCGGCAACGGCCTGGAGTGGGTGGCCTTCATGAGCTACGACGGCAGCAACAAGAAGTAC
GCCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACAGCAAGAACACCCTGTAC
CTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAGGGACAGG
GGCATCGCCGCCGGCGGCAACTACTACTACTACGGCATGGACGTGTGGGGCCAGGGCACC
ACCGTGACCGTGAGCAGC
>P01274_F03 guselkumab
GAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCGAGAGCCTGAAGATC
AGCTGCAAGGGCAGCGGCTACAGCTTCAGCAACTACTGGATCGGCTGGGTGAGGCAGATG
CCCGGCAAGGGCCTGGAGTGGATGGGCATCATCGACCCCAGCAACAGCTACACCAGGTAC
AGCCCCAGCTTCCAGGGCCAGGTGACCATCAGCGCCGACAAGAGCATCAGCACCGCCTAC
CTGCAGTGGAGCAGCCTGAAGGCCAGCGACACCGCCATGTACTACTGCGCCAGGTGGTAC
TACAAGCCCTTCGACGTGTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
>P01274_F04 ibalizumab
CAGGTGCAGCTGCAGCAGAGCGGCCCCGAGGTGGTGAAGCCCGGCGCCAGCGTGAAGATG
AGCTGCAAGGCCAGCGGCTACACCTTCACCAGCTACGTGATCCACTGGGTGAGGCAGAAG
CCCGGCCAGGGCCTGGACTGGATCGGCTACATCAACCCCTACAACGACGGCACCGACTAC
GACGAGAAGTTCAAGGGCAAGGCCACCCTGACCAGCGACACCAGCACCAGCACCGCCTAC
ATGGAGCTGAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTACTGCGCCAGGGAGAAG
GACAACTACGCCACCGGCGCCTGGTTCGCCTACTGGGGCCAGGGCACCCTGGTGACCGTG
AGCAGC
>P01274_F05 imgatuzumab
CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCAGCAGCGTGAAGGTG
AGCTGCAAGGCCAGCGGCTTCACCTTCACCGACTACAAGATCCACTGGGTGAGGCAGGCC
CCCGGCCAGGGCCTGGAGTGGATGGGCTACTTCAACCCCAACAGCGGCTACAGCACCTAC
GCCCAGAAGTTCCAGGGCAGGGTGACCATCACCGCCGACAAGAGCACCAGCACCGCCTAC
ATGGAGCTGAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTACTGCGCCAGGCTGAGC
CCCGGCGGCTACTACGTGATGGACGCCTGGGGCCAGGGCACCACCGTGACCGTGAGCAGC
>P01274_F06 infliximab
GAGGTGAAGCTGGAGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCATGAAGCTG
AGCTGCGTGGCCAGCGGCTTCATCTTCAGCAACCACTGGATGAACTGGGTGAGGCAGAGC
CCCGAGAAGGGCCTGGAGTGGGTGGCCGAGATCAGGAGCAAGAGCATCAACAGCGCCACC
CACTACGCCGAGAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACGACAGCAAGAGCGCC
GTGTACCTGCAGATGACCGACCTGAGGACCGAGGACACCGGCGTGTACTACTGCAGCAGG
AACTACTACGGCAGCACCTACGACTACTGGGGCCAGGGCACCACCCTGACCGTGAGCAGC
>P01274_F07 inotuzumab
GAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCGCCAGCGTGAAGGTG
AGCTGCAAGGCCAGCGGCTACAGGTTCACCAACTACTGGATCCACTGGGTGAGGCAGGCC
CCCGGCCAGGGCCTGGAGTGGATCGGCGGCATCAACCCCGGCAACAACTACGCCACCTAC
AGGAGGAAGTTCCAGGGCAGGGTGACCATGACCGCCGACACCAGCACCAGCACCGTGTAC
ATGGAGCTGAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTACTGCACCAGGGAGGGC
TACGGCAACTACGGCGCCTGGTTCGCCTACTGGGGCCAGGGCACCCTGGTGACCGTGAGC
AGC
>P01274_F08 ipilimumab
CAGGTGCAGCTGGTGGAGAGCGGCGGCGGCGTGGTGCAGCCCGGCAGGAGCCTGAGGCTG
AGCTGCGCCGCCAGCGGCTTCACCTTCAGCAGCTACACCATGCACTGGGTGAGGCAGGCC
CCCGGCAAGGGCCTGGAGTGGGTGACCTTCATCAGCTACGACGGCAACAACAAGTACTAC
GCCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACAGCAAGAACACCCTGTAC
CTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCATCTACTACTGCGCCAGGACCGGC
TGGCTGGGCCCCTTCGACTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
>P01274_F09 ixekizumab
CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCAGCAGCGTGAAGGTG
AGCTGCAAGGCCAGCGGCTACAGCTTCACCGACTACCACATCCACTGGGTGAGGCAGGCC
CCCGGCCAGGGCCTGGAGTGGATGGGCGTGATCAACCCCATGTACGGCACCACCGACTAC
AACCAGAGGTTCAAGGGCAGGGTGACCATCACCGCCGACGAGAGCACCAGCACCGCCTAC
ATGGAGCTGAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTACTGCGCCAGGTACGAC
TACTTCACCGGCACCGGCGTGTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
>P01274_F10 lampalizumab
GAGGTGCAGCTGGTGCAGAGCGGCCCCGAGCTGAAGAAGCCCGGCGCCAGCGTGAAGGTG
AGCTGCAAGGCCAGCGGCTACACCTTCACCAACTACGGCATGAACTGGGTGAGGCAGGCC
CCCGGCCAGGGCCTGGAGTGGATGGGCTGGATCAACACCTACACCGGCGAGACCACCTAC
GCCGACGACTTCAAGGGCAGGTTCGTGTTCAGCCTGGACACCAGCGTGAGCACCGCCTAC
CTGCAGATCAGCAGCCTGAAGGCCGAGGACACCGCCGTGTACTACTGCGAGAGGGAGGGC
GGCGTGAACAACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
>P01274_F11 lebrikizumab
CAGGTGACCCTGAGGGAGAGCGGCCCCGCCCTGGTGAAGCCCACCCAGACCCTGACCCTG
ACCTGCACCGTGAGCGGCTTCAGCCTGAGCGCCTACAGCGTGAACTGGATCAGGCAGCCC
CCCGGCAAGGCCCTGGAGTGGCTGGCCATGATCTGGGGCGACGGCAAGATCGTGTACAAC
AGCGCCCTGAAGAGCAGGCTGACCATCAGCAAGGACACCAGCAAGAACCAGGTGGTGCTG
ACCATGACCAACATGGACCCCGTGGACACCGCCACCTACTACTGCGCCGGCGACGGCTAC
TACCCCTACGCCATGGACAACTGGGGCCAGGGCAGCCTGGTGACCGTGAGCAGC
>P01274_F12 lenzilumab
CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCGCCAGCGTGAAGGTG
AGCTGCAAGGCCAGCGGCTACAGCTTCACCAACTACTACATCCACTGGGTGAGGCAGGCC
CCCGGCCAGAGGCTGGAGTGGATGGGCTGGATCAACGCCGGCAACGGCAACACCAAGTAC
AGCCAGAAGTTCCAGGGCAGGGTGACCATCACCAGGGACACCAGCGCCAGCACCGCCTAC
ATGGAGCTGAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTACTGCGTGAGGAGGCAG
AGGTTCCCCTACTACTTCGACTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
>P01274_G01 lintuzumab
CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCAGCAGCGTGAAGGTG
AGCTGCAAGGCCAGCGGCTACACCTTCACCGACTACAACATGCACTGGGTGAGGCAGGCC
CCCGGCCAGGGCCTGGAGTGGATCGGCTACATCTACCCCTACAACGGCGGCACCGGCTAC
AACCAGAAGTTCAAGAGCAAGGCCACCATCACCGCCGACGAGAGCACCAACACCGCCTAC
ATGGAGCTGAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTACTGCGCCAGGGGCAGG
CCCGCCATGGACTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
>P01274_G02 lirilumab
CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCAGCAGCGTGAAGGTG
AGCTGCAAGGCCAGCGGCGGCACCTTCAGCTTCTACGCCATCAGCTGGGTGAGGCAGGCC
CCCGGCCAGGGCCTGGAGTGGATGGGCGGCTTCATCCCCATCTTCGGCGCCGCCAACTAC
GCCCAGAAGTTCCAGGGCAGGGTGACCATCACCGCCGACGAGAGCACCAGCACCGCCTAC
ATGGAGCTGAGCAGCCTGAGGAGCGACGACACCGCCGTGTACTACTGCGCCAGGATCCCC
AGCGGCAGCTACTACTACGACTACGACATGGACGTGTGGGGCCAGGGCACCACCGTGACC
GTGAGCAGC
>P01274_G03 lumiliximab
GAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGCCAAGCCCGGCGGCAGCCTGAGGCTG
AGCTGCGCCGCCAGCGGCTTCAGGTTCACCTTCAACAACTACTACATGGACTGGGTGAGG
CAGGCCCCCGGCCAGGGCCTGGAGTGGGTGAGCAGGATCAGCAGCAGCGGCGACCCCACC
TGGTACGCCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGAGAACGCCAACAACACC
CTGTTCCTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAGC
CTGACCACCGGCAGCGACAGCTGGGGCCAGGGCGTGCTGGTGACCGTGAGCAGC
>P01274_G04 matuzumab
CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCGCCAGCGTGAAGGTG
AGCTGCAAGGCCAGCGGCTACACCTTCACCAGCCACTGGATGCACTGGGTGAGGCAGGCC
CCCGGCCAGGGCCTGGAGTGGATCGGCGAGTTCAACCCCAGCAACGGCAGGACCAACTAC
AACGAGAAGTTCAAGAGCAAGGCCACCATGACCGTGGACACCAGCACCAACACCGCCTAC
ATGGAGCTGAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTACTGCGCCAGCAGGGAC
TACGACTACGACGGCAGGTACTTCGACTACTGGGGCCAGGGCACCCTGGTGACCGTGAGC
AGC
>P01274_G05 mavrilimumab
CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCGCCAGCGTGAAGGTG
AGCTGCAAGGTGAGCGGCTACACCCTGACCGAGCTGAGCATCCACTGGGTGAGGCAGGCC
CCCGGCAAGGGCCTGGAGTGGATGGGCGGCTTCGACCCCGAGGAGAACGAGATCGTGTAC
GCCCAGAGGTTCCAGGGCAGGGTGACCATGACCGAGGACACCAGCACCGACACCGCCTAC
ATGGAGCTGAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTACTGCGCCATCGTGGGC
AGCTTCAGCCCCCTGACCCTGGGCCTGTGGGGCCAGGGCACCATGGTGACCGTGAGCAGC
>P01274_G06 mepolizumab
CAGGTGACCCTGAGGGAGAGCGGCCCCGCCCTGGTGAAGCCCACCCAGACCCTGACCCTG
ACCTGCACCGTGAGCGGCTTCAGCCTGACCAGCTACAGCGTGCACTGGGTGAGGCAGCCC
CCCGGCAAGGGCCTGGAGTGGCTGGGCGTGATCTGGGCCAGCGGCGGCACCGACTACAAC
AGCGCCCTGATGAGCAGGCTGAGCATCAGCAAGGACACCAGCAGGAACCAGGTGGTGCTG
ACCATGACCAACATGGACCCCGTGGACACCGCCACCTACTACTGCGCCAGGGACCCCCCC
AGCAGCCTGCTGAGGCTGGACTACTGGGGCAGGGGCACCCCCGTGACCGTGAGCAGC
>P01274_G07 mogamulizumab
GAGGTGCAGCTGGTGGAGAGCGGCGGCGACCTGGTGCAGCCCGGCAGGAGCCTGAGGCTG
AGCTGCGCCGCCAGCGGCTTCATCTTCAGCAACTACGGCATGAGCTGGGTGAGGCAGGCC
CCCGGCAAGGGCCTGGAGTGGGTGGCCACCATCAGCAGCGCCAGCACCTACAGCTACTAC
CCCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACGCCAAGAACAGCCTGTAC
CTGCAGATGAACAGCCTGAGGGTGGAGGACACCGCCCTGTACTACTGCGGCAGGCACAGC
GACGGCAACTTCGCCTTCGGCTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
>P01274_G08 motavizumab
CAGGTGACCCTGAGGGAGAGCGGCCCCGCCCTGGTGAAGCCCACCCAGACCCTGACCCTG
ACCTGCACCTTCAGCGGCTTCAGCCTGAGCACCGCCGGCATGAGCGTGGGCTGGATCAGG
CAGCCCCCCGGCAAGGCCCTGGAGTGGCTGGCCGACATCTGGTGGGACGACAAGAAGCAC
TACAACCCCAGCCTGAAGGACAGGCTGACCATCAGCAAGGACACCAGCAAGAACCAGGTG
GTGCTGAAGGTGACCAACATGGACCCCGCCGACACCGCCACCTACTACTGCGCCAGGGAC
ATGATCTTCAACTTCTACTTCGACGTGTGGGGCCAGGGCACCACCGTGACCGTGAGCAGC
>P01274_G09 muromonab
CAGGTGCAGCTGCAGCAGAGCGGCGCCGAGCTGGCCAGGCCCGGCGCCAGCGTGAAGATG
AGCTGCAAGGCCAGCGGCTACACCTTCACCAGGTACACCATGCACTGGGTGAAGCAGAGG
CCCGGCCAGGGCCTGGAGTGGATCGGCTACATCAACCCCAGCAGGGGCTACACCAACTAC
AACCAGAAGTTCAAGGACAAGGCCACCCTGACCACCGACAAGAGCAGCAGCACCGCCTAC
ATGCAGCTGAGCAGCCTGACCAGCGAGGACAGCGCCGTGTACTACTGCGCCAGGTACTAC
GACGACCACTACTGCCTGGACTACTGGGGCCAGGGCACCACCCTGACCGTGAGCAGC
>P01274_G10 natalizumab
CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCGCCAGCGTGAAGGTG
AGCTGCAAGGCCAGCGGCTTCAACATCAAGGACACCTACATCCACTGGGTGAGGCAGGCC
CCCGGCCAGAGGCTGGAGTGGATGGGCAGGATCGACCCCGCCAACGGCTACACCAAGTAC
GACCCCAAGTTCCAGGGCAGGGTGACCATCACCGCCGACACCAGCGCCAGCACCGCCTAC
ATGGAGCTGAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTACTGCGCCAGGGAGGGC
TACTACGGCAACTACGGCGTGTACGCCATGGACTACTGGGGCCAGGGCACCCTGGTGACC
GTGAGCAGC
>P01274_G11 necitumumab
CAGGTGCAGCTGCAGGAGAGCGGCCCCGGCCTGGTGAAGCCCAGCCAGACCCTGAGCCTG
ACCTGCACCGTGAGCGGCGGCAGCATCAGCAGCGGCGACTACTACTGGAGCTGGATCAGG
CAGCCCCCCGGCAAGGGCCTGGAGTGGATCGGCTACATCTACTACAGCGGCAGCACCGAC
TACAACCCCAGCCTGAAGAGCAGGGTGACCATGAGCGTGGACACCAGCAAGAACCAGTTC
AGCCTGAAGGTGAACAGCGTGACCGCCGCCGACACCGCCGTGTACTACTGCGCCAGGGTG
AGCATCTTCGGCGTGGGCACCTTCGACTACTGGGGCCAGGGCACCCTGGTGACCGTGAGC
AGC
>P01274_G12 nimotuzumab
CAGGTGCAGCTGCAGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCAGCAGCGTGAAGGTG
AGCTGCAAGGCCAGCGGCTACACCTTCACCAACTACTACATCTACTGGGTGAGGCAGGCC
CCCGGCCAGGGCCTGGAGTGGATCGGCGGCATCAACCCCACCAGCGGCGGCAGCAACTTC
AACGAGAAGTTCAAGACCAGGGTGACCATCACCGCCGACGAGAGCAGCACCACCGCCTAC
ATGGAGCTGAGCAGCCTGAGGAGCGAGGACACCGCCTTCTACTTCTGCACCAGGCAGGGC
CTGTGGTTCGACAGCGACGGCAGGGGCTTCGACTTCTGGGGCCAGGGCACCACCGTGACC
GTGAGCAGC
>P01274_H01 nivolumab
CAGGTGCAGCTGGTGGAGAGCGGCGGCGGCGTGGTGCAGCCCGGCAGGAGCCTGAGGCTG
GACTGCAAGGCCAGCGGCATCACCTTCAGCAACAGCGGCATGCACTGGGTGAGGCAGGCC
CCCGGCAAGGGCCTGGAGTGGGTGGCCGTGATCTGGTACGACGGCAGCAAGAGGTACTAC
GCCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACAGCAAGAACACCCTGTTC
CTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCACCAACGAC
GACTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
>P01274_H02 obinutuzumab
CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCAGCAGCGTGAAGGTG
AGCTGCAAGGCCAGCGGCTACGCCTTCAGCTACAGCTGGATCAACTGGGTGAGGCAGGCC
CCCGGCCAGGGCCTGGAGTGGATGGGCAGGATCTTCCCCGGCGACGGCGACACCGACTAC
AACGGCAAGTTCAAGGGCAGGGTGACCATCACCGCCGACAAGAGCACCAGCACCGCCTAC
ATGGAGCTGAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTACTGCGCCAGGAACGTG
TTCGACGGCTACTGGCTGGTGTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
>P01274_H03 ocrelizumab
GAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCTG
AGCTGCGCCGCCAGCGGCTACACCTTCACCAGCTACAACATGCACTGGGTGAGGCAGGCC
CCCGGCAAGGGCCTGGAGTGGGTGGGCGCCATCTACCCCGGCAACGGCGACACCAGCTAC
AACCAGAAGTTCAAGGGCAGGTTCACCATCAGCGTGGACAAGAGCAAGAACACCCTGTAC
CTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAGGGTGGTG
TACTACAGCAACAGCTACTGGTACTTCGACGTGTGGGGCCAGGGCACCCTGGTGACCGTG
AGCAGC
>P01274_H04 ofatumumab
GAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCAGGAGCCTGAGGCTG
AGCTGCGCCGCCAGCGGCTTCACCTTCAACGACTACGCCATGCACTGGGTGAGGCAGGCC
CCCGGCAAGGGCCTGGAGTGGGTGAGCACCATCAGCTGGAACAGCGGCAGCATCGGCTAC
GCCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACGCCAAGAAGAGCCTGTAC
CTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCCTGTACTACTGCGCCAAGGACATC
CAGTACGGCAACTACTACTACGGCATGGACGTGTGGGGCCAGGGCACCACCGTGACCGTG
AGCAGC
>P01274_H05 olaratumab
CAGCTGCAGCTGCAGGAGAGCGGCCCCGGCCTGGTGAAGCCCAGCGAGACCCTGAGCCTG
ACCTGCACCGTGAGCGGCGGCAGCATCAACAGCAGCAGCTACTACTGGGGCTGGCTGAGG
CAGAGCCCCGGCAAGGGCCTGGAGTGGATCGGCAGCTTCTTCTACACCGGCAGCACCTAC
TACAACCCCAGCCTGAGGAGCAGGCTGACCATCAGCGTGGACACCAGCAAGAACCAGTTC
AGCCTGATGCTGAGCAGCGTGACCGCCGCCGACACCGCCGTGTACTACTGCGCCAGGCAG
AGCACCTACTACTACGGCAGCGGCAACTACTACGGCTGGTTCGACAGGTGGGACCAGGGC
ACCCTGGTGACCGTGAGCAGC
>P01274_H06 olokizumab
GAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCTG
AGCTGCGCCGCCAGCGGCTTCAACTTCAACGACTACTTCATGAACTGGGTGAGGCAGGCC
CCCGGCAAGGGCCTGGAGTGGGTGGCCCAGATGAGGAACAAGAACTACCAGTACGGCACC
TACTACGCCGAGAGCCTGGAGGGCAGGTTCACCATCAGCAGGGACGACAGCAAGAACAGC
CTGTACCTGCAGATGAACAGCCTGAAGACCGAGGACACCGCCGTGTACTACTGCGCCAGG
GAGAGCTACTACGGCTTCACCAGCTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
>P01274_H07 omalizumab
GAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCTG
AGCTGCGCCGTGAGCGGCTACAGCATCACCAGCGGCTACAGCTGGAACTGGATCAGGCAG
GCCCCCGGCAAGGGCCTGGAGTGGGTGGCCAGCATCACCTACGACGGCAGCACCAACTAC
AACCCCAGCCTGAAGGGCAGGATCACCATCAGCAGGGACGACAGCAAGAACACCTTCTAC
CTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAGGGGCAGC
CACTACTTCGGCCACTGGCACTTCGCCGTGTGGGGCCAGGGCACCCTGGTGACCGTGAGC
AGC
>P01274_H08 onartuzumab
GAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCTG
AGCTGCGCCGCCAGCGGCTACACCTTCACCAGCTACTGGCTGCACTGGGTGAGGCAGGCC
CCCGGCAAGGGCCTGGAGTGGGTGGGCATGATCGACCCCAGCAACAGCGACACCAGGTTC
AACCCCAACTTCAAGGACAGGTTCACCATCAGCGCCGACACCAGCAAGAACACCGCCTAC
CTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCACCTACAGG
AGCTACGTGACCCCCCTGGACTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
>P01274_H09 otelixizumab
GAGGTGCAGCTGCTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCTG
AGCTGCGCCGCCAGCGGCTTCACCTTCAGCAGCTTCCCCATGGCCTGGGTGAGGCAGGCC
CCCGGCAAGGGCCTGGAGTGGGTGAGCACCATCAGCACCAGCGGCGGCAGGACCTACTAC
AGGGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACAGCAAGAACACCCTGTAC
CTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAAGTTCAGG
CAGTACAGCGGCGGCTTCGACTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
>P01274_H10 otlertuzumab
GAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCGAGAGCCTGAAGATC
AGCTGCAAGGGCAGCGGCTACAGCTTCACCGGCTACAACATGAACTGGGTGAGGCAGATG
CCCGGCAAGGGCCTGGAGTGGATGGGCAACATCGACCCCTACTACGGCGGCACCACCTAC
AACAGGAAGTTCAAGGGCCAGGTGACCATCAGCGCCGACAAGAGCATCAGCACCGCCTAC
CTGCAGTGGAGCAGCCTGAAGGCCAGCGACACCGCCATGTACTACTGCGCCAGGAGCGTG
GGCCCCTTCGACAGCTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
>P01274_H11 ozanezumab
CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCGCCAGCGTGAAGGTG
AGCTGCAAGGCCAGCGGCTACACCTTCACCAGCTACTGGATGCACTGGGTGAGGCAGGCC
CCCGGCCAGGGCCTGGAGTGGATCGGCAACATCAACCCCAGCAACGGCGGCACCAACTAC
AACGAGAAGTTCAAGAGCAAGGCCACCATGACCAGGGACACCAGCACCAGCACCGCCTAC
ATGGAGCTGAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTACTGCGAGCTGATGCAG
GGCTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
>P01274_H12 palivizumab
CAGGTGACCCTGAGGGAGAGCGGCCCCGCCCTGGTGAAGCCCACCCAGACCCTGACCCTG
ACCTGCACCTTCAGCGGCTTCAGCCTGAGCACCAGCGGCATGAGCGTGGGCTGGATCAGG
CAGCCCCCCGGCAAGGCCCTGGAGTGGCTGGCCGACATCTGGTGGGACGACAAGAAGGAC
TACAACCCCAGCCTGAAGAGCAGGCTGACCATCAGCAAGGACACCAGCAAGAACCAGGTG
GTGCTGAAGGTGACCAACATGGACCCCGCCGACACCGCCACCTACTACTGCGCCAGGAGC
ATGATCACCAACTGGTACTTCGACGTGTGGGGCGCCGGCACCACCGTGACCGTGAGCAGC
>P00483_A01 panitumumab
CAGGTGCAGCTGCAGGAGAGCGGCCCCGGCCTGGTGAAGCCCAGCGAGACCCTGAGCCTG
ACCTGCACCGTGAGCGGCGGCAGCGTGAGCAGCGGCGACTACTACTGGACCTGGATCAGG
CAGAGCCCCGGCAAGGGCCTGGAGTGGATCGGCCACATCTACTACAGCGGCAACACCAAC
TACAACCCCAGCCTGAAGAGCAGGCTGACCATCAGCATCGACACCAGCAAGACCCAGTTC
AGCCTGAAGCTGAGCAGCGTGACCGCCGCCGACACCGCCATCTACTACTGCGTGAGGGAC
AGGGTGACCGGCGCCTTCGACATCTGGGGCCAGGGCACCATGGTGACCGTGAGCAGC
>P00483_A02 panobacumab
GAGGAGCAGGTGGTGGAGAGCGGCGGCGGCTTCGTGCAGCCCGGCGGCAGCCTGAGGCTG
AGCTGCGCCGCCAGCGGCTTCACCTTCAGCCCCTACTGGATGCACTGGGTGAGGCAGGCC
CCCGGCAAGGGCCTGGTGTGGGTGAGCAGGATCAACAGCGACGGCAGCACCTACTACGCC
GACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACGCCAGGAACACCCTGTACCTG
CAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAGGGACAGGTAC
TACGGCCCCGAGATGTGGGGCCAGGGCACCATGGTGACCGTGAGCAGC
>P00483_A03 parsatuzumab
GAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCTG
AGCTGCGCCGCCAGCGGCTACACCTTCATCGACTACTACATGAACTGGGTGAGGCAGGCC
CCCGGCAAGGGCCTGGAGTGGGTGGGCGACATCAACCTGGACAACAGCGGCACCCACTAC
AACCAGAAGTTCAAGGGCAGGTTCACCATCAGCAGGGACAAGAGCAAGAACACCGCCTAC
CTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAGGGAGGGC
GTGTACCACGACTACGACGACTACGCCATGGACTACTGGGGCCAGGGCACCCTGGTGACC
GTGAGCAGC
>P00483_A04 patritumab
CAGGTGCAGCTGCAGCAGTGGGGCGCCGGCCTGCTGAAGCCCAGCGAGACCCTGAGCCTG
ACCTGCGCCGTGTACGGCGGCAGCTTCAGCGGCTACTACTGGAGCTGGATCAGGCAGCCC
CCCGGCAAGGGCCTGGAGTGGATCGGCGAGATCAACCACAGCGGCAGCACCAACTACAAC
CCCAGCCTGAAGAGCAGGGTGACCATCAGCGTGGAGACCAGCAAGAACCAGTTCAGCCTG
AAGCTGAGCAGCGTGACCGCCGCCGACACCGCCGTGTACTACTGCGCCAGGGACAAGTGG
ACCTGGTACTTCGACCTGTGGGGCAGGGGCACCCTGGTGACCGTGAGCAGC
>P00483_A05 pembrolizumab
CAGGTGCAGCTGGTGCAGAGCGGCGTGGAGGTGAAGAAGCCCGGCGCCAGCGTGAAGGTG
AGCTGCAAGGCCAGCGGCTACACCTTCACCAACTACTACATGTACTGGGTGAGGCAGGCC
CCCGGCCAGGGCCTGGAGTGGATGGGCGGCATCAACCCCAGCAACGGCGGCACCAACTTC
AACGAGAAGTTCAAGAACAGGGTGACCCTGACCACCGACAGCAGCACCACCACCGCCTAC
ATGGAGCTGAAGAGCCTGCAGTTCGACGACACCGCCGTGTACTACTGCGCCAGGAGGGAC
TACAGGTTCGACATGGGCTTCGACTACTGGGGCCAGGGCACCACCGTGACCGTGAGCAGC
>P00483_A06 pertuzumab
GAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCTG
AGCTGCGCCGCCAGCGGCTTCACCTTCACCGACTACACCATGGACTGGGTGAGGCAGGCC
CCCGGCAAGGGCCTGGAGTGGGTGGCCGACGTGAACCCCAACAGCGGCGGCAGCATCTAC
AACCAGAGGTTCAAGGGCAGGTTCACCCTGAGCGTGGACAGGAGCAAGAACACCCTGTAC
CTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAGGAACCTG
GGCCCCAGCTTCTACTTCGACTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
>P00483_A07 pinatuzumab
GAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCTG
AGCTGCGCCGCCAGCGGCTACGAGTTCAGCAGGAGCTGGATGAACTGGGTGAGGCAGGCC
CCCGGCAAGGGCCTGGAGTGGGTGGGCAGGATCTACCCCGGCGACGGCGACACCAACTAC
AGCGGCAAGTTCAAGGGCAGGTTCACCATCAGCGCCGACACCAGCAAGAACACCGCCTAC
CTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAGGGACGGC
AGCAGCTGGGACTGGTACTTCGACGTGTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
>P00483_A08 polatuzumab
GAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCTG
AGCTGCGCCGCCAGCGGCTACACCTTCAGCAGCTACTGGATCGAGTGGGTGAGGCAGGCC
CCCGGCAAGGGCCTGGAGTGGATCGGCGAGATCCTGCCCGGCGGCGGCGACACCAACTAC
AACGAGATCTTCAAGGGCAGGGCCACCTTCAGCGCCGACACCAGCAAGAACACCGCCTAC
CTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCACCAGGAGGGTG
CCCATCAGGCTGGACTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
>P00483_A09 ponezumab
CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCGCCAGCGTGAAGGTG
AGCTGCAAGGCCAGCGGCTACTACACCGAGGCCTACTACATCCACTGGGTGAGGCAGGCC
CCCGGCCAGGGCCTGGAGTGGATGGGCAGGATCGACCCCGCCACCGGCAACACCAAGTAC
GCCCCCAGGCTGCAGGACAGGGTGACCATGACCAGGGACACCAGCACCAGCACCGTGTAC
ATGGAGCTGAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTACTGCGCCAGCCTGTAC
AGCCTGCCCGTGTACTGGGGCCAGGGCACCACCGTGACCGTGAGCAGC
>P00483_A10 radretumab
GAGGTGCAGCTGCTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCTG
AGCTGCGCCGCCAGCGGCTTCACCTTCAGCAGCTTCAGCATGAGCTGGGTGAGGCAGGCC
CCCGGCAAGGGCCTGGAGTGGGTGAGCAGCATCAGCGGCAGCAGCGGCACCACCTACTAC
GCCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACAGCAAGAACACCCTGTAC
CTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAAGCCCTTC
CCCTACTTCGACTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
>P00483_A11 ramucirumab
GAGGTGCAGCTGGTGCAGAGCGGCGGCGGCCTGGTGAAGCCCGGCGGCAGCCTGAGGCTG
AGCTGCGCCGCCAGCGGCTTCACCTTCAGCAGCTACAGCATGAACTGGGTGAGGCAGGCC
CCCGGCAAGGGCCTGGAGTGGGTGAGCAGCATCAGCAGCAGCAGCAGCTACATCTACTAC
GCCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACGCCAAGAACAGCCTGTAC
CTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAGGGTGACC
GACGCCTTCGACATCTGGGGCCAGGGCACCATGGTGACCGTGAGCAGC
>P00483_A12 ranibizumab
GAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCTG
AGCTGCGCCGCCAGCGGCTACGACTTCACCCACTACGGCATGAACTGGGTGAGGCAGGCC
CCCGGCAAGGGCCTGGAGTGGGTGGGCTGGATCAACACCTACACCGGCGAGCCCACCTAC
GCCGCCGACTTCAAGAGGAGGTTCACCTTCAGCCTGGACACCAGCAAGAGCACCGCCTAC
CTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAAGTACCCC
TACTACTACGGCACCAGCCACTGGTACTTCGACGTGTGGGGCCAGGGCACCCTGGTGACC
GTGAGCAGC
>P00483_B01 reslizumab
GAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCTG
AGCTGCGCCGTGAGCGGCCTGAGCCTGACCAGCAACAGCGTGAACTGGATCAGGCAGGCC
CCCGGCAAGGGCCTGGAGTGGGTGGGCCTGATCTGGAGCAACGGCGACACCGACTACAAC
AGCGCCATCAAGAGCAGGTTCACCATCAGCAGGGACACCAGCAAGAGCACCGTGTACCTG
CAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAGGGAGTACTAC
GGCTACTTCGACTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
>P00483_B02 rilotumumab
CAGGTGCAGCTGCAGGAGAGCGGCCCCGGCCTGGTGAAGCCCAGCGAGACCCTGAGCCTG
ACCTGCACCGTGAGCGGCGGCAGCATCAGCATCTACTACTGGAGCTGGATCAGGCAGCCC
CCCGGCAAGGGCCTGGAGTGGATCGGCTACGTGTACTACAGCGGCAGCACCAACTACAAC
CCCAGCCTGAAGAGCAGGGTGACCATCAGCGTGGACACCAGCAAGAACCAGTTCAGCCTG
AAGCTGAACAGCGTGACCGCCGCCGACACCGCCGTGTACTACTGCGCCAGGGGCGGCTAC
GACTTCTGGAGCGGCTACTTCGACTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
>P00483_B03 rituximab
CAGGTGCAGCTGCAGCAGCCCGGCGCCGAGCTGGTGAAGCCCGGCGCCAGCGTGAAGATG
AGCTGCAAGGCCAGCGGCTACACCTTCACCAGCTACAACATGCACTGGGTGAAGCAGACC
CCCGGCAGGGGCCTGGAGTGGATCGGCGCCATCTACCCCGGCAACGGCGACACCAGCTAC
AACCAGAAGTTCAAGGGCAAGGCCACCCTGACCGCCGACAAGAGCAGCAGCACCGCCTAC
ATGCAGCTGAGCAGCCTGACCAGCGAGGACAGCGCCGTGTACTACTGCGCCAGGAGCACC
TACTACGGCGGCGACTGGTACTTCAACGTGTGGGGCGCCGGCACCACCGTGACCGTGAGC
GCC
>P00483_B04 robatumumab
GAGGTGCAGCTGGTGCAGAGCGGCGGCGGCCTGGTGAAGCCCGGCGGCAGCCTGAGGCTG
AGCTGCGCCGCCAGCGGCTTCACCTTCAGCAGCTTCGCCATGCACTGGGTGAGGCAGGCC
CCCGGCAAGGGCCTGGAGTGGATCAGCGTGATCGACACCAGGGGCGCCACCTACTACGCC
GACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACGCCAAGAACAGCCTGTACCTG
CAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAGGCTGGGCAAC
TTCTACTACGGCATGGACGTGTGGGGCCAGGGCACCACCGTGACCGTGAGCAGC
>P00483_B05 romosozumab
GAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCGCCAGCGTGAAGGTG
AGCTGCAAGGCCAGCGGCTACACCTTCACCGACTACAACATGCACTGGGTGAGGCAGGCC
CCCGGCCAGGGCCTGGAGTGGATGGGCGAGATCAACCCCAACAGCGGCGGCGCCGGCTAC
AACCAGAAGTTCAAGGGCAGGGTGACCATGACCACCGACACCAGCACCAGCACCGCCTAC
ATGGAGCTGAGGAGCCTGAGGAGCGACGACACCGCCGTGTACTACTGCGCCAGGCTGGGC
TACGACGACATCTACGACGACTGGTACTTCGACGTGTGGGGCCAGGGCACCACCGTGACC
GTGAGCAGC
>P00483_B06 sarilumab
GAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCAGGAGCCTGAGGCTG
AGCTGCGCCGCCAGCAGGTTCACCTTCGACGACTACGCCATGCACTGGGTGAGGCAGGCC
CCCGGCAAGGGCCTGGAGTGGGTGAGCGGCATCAGCTGGAACAGCGGCAGGATCGGCTAC
GCCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACGCCGAGAACAGCCTGTTC
CTGCAGATGAACGGCCTGAGGGCCGAGGACACCGCCCTGTACTACTGCGCCAAGGGCAGG
GACAGCTTCGACATCTGGGGCCAGGGCACCATGGTGACCGTGAGCAGC
>P00483_B07 secukinumab
GAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCTG
AGCTGCGCCGCCAGCGGCTTCACCTTCAGCAACTACTGGATGAACTGGGTGAGGCAGGCC
CCCGGCAAGGGCCTGGAGTGGGTGGCCGCCATCAACCAGGACGGCAGCGAGAAGTACTAC
GTGGGCAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACGCCAAGAACAGCCTGTAC
CTGCAGATGAACAGCCTGAGGGTGGAGGACACCGCCGTGTACTACTGCGTGAGGGACTAC
TACGACATCCTGACCGACTACTACATCCACTACTGGTACTTCGACCTGTGGGGCAGGGGC
ACCCTGGTGACCGTGAGCAGC
>P00483_B08 seribantumab
GAGGTGCAGCTGCTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCTG
AGCTGCGCCGCCAGCGGCTTCACCTTCAGCCACTACGTGATGGCCTGGGTGAGGCAGGCC
CCCGGCAAGGGCCTGGAGTGGGTGAGCAGCATCAGCAGCAGCGGCGGCTGGACCCTGTAC
GCCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACAGCAAGAACACCCTGTAC
CTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCACCAGGGGCCTG
AAGATGGCCACCATCTTCGACTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
>P00483_B09 sifalimumab
CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCGCCAGCGTGAAGGTG
AGCTGCAAGGCCAGCGGCTACACCTTCACCAGCTACAGCATCAGCTGGGTGAGGCAGGCC
CCCGGCCAGGGCCTGGAGTGGATGGGCTGGATCAGCGTGTACAACGGCAACACCAACTAC
GCCCAGAAGTTCCAGGGCAGGGTGACCATGACCACCGACACCAGCACCAGCACCGCCTAC
CTGGAGCTGAGGAGCCTGAGGAGCGACGACACCGCCGTGTACTACTGCGCCAGGGACCCC
ATCGCCGCCGGCTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
>P00483_B10 siltuximab
GAGGTGCAGCTGGTGGAGAGCGGCGGCAAGCTGCTGAAGCCCGGCGGCAGCCTGAAGCTG
AGCTGCGCCGCCAGCGGCTTCACCTTCAGCAGCTTCGCCATGAGCTGGTTCAGGCAGAGC
CCCGAGAAGAGGCTGGAGTGGGTGGCCGAGATCAGCAGCGGCGGCAGCTACACCTACTAC
CCCGACACCGTGACCGGCAGGTTCACCATCAGCAGGGACAACGCCAAGAACACCCTGTAC
CTGGAGATGAGCAGCCTGAGGAGCGAGGACACCGCCATGTACTACTGCGCCAGGGGCCTG
TGGGGCTACTACGCCCTGGACTACTGGGGCCAGGGCACCAGCGTGACCGTGAGCAGC
>P00483_B11 simtuzumab
CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCGCCAGCGTGAAGGTG
AGCTGCAAGGCCAGCGGCTACGCCTTCACCTACTACCTGATCGAGTGGGTGAGGCAGGCC
CCCGGCCAGGGCCTGGAGTGGATCGGCGTGATCAACCCCGGCAGCGGCGGCACCAACTAC
AACGAGAAGTTCAAGGGCAGGGCCACCATCACCGCCGACAAGAGCACCAGCACCGCCTAC
ATGGAGCTGAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTTCTGCGCCAGGAACTGG
ATGAACTTCGACTACTGGGGCCAGGGCACCACCGTGACCGTGAGCAGC
>P00483_B12 sirukumab
GAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCTG
AGCTGCGCCGCCAGCGGCTTCACCTTCAGCCCCTTCGCCATGAGCTGGGTGAGGCAGGCC
CCCGGCAAGGGCCTGGAGTGGGTGGCCAAGATCAGCCCCGGCGGCAGCTGGACCTACTAC
AGCGACACCGTGACCGGCAGGTTCACCATCAGCAGGGACAACGCCAAGAACAGCCTGTAC
CTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAGGCAGCTG
TGGGGCTACTACGCCCTGGACATCTGGGGCCAGGGCACCACCGTGACCGTGAGCAGC
>P00483_C01 tabalumab
CAGGTGCAGCTGCAGCAGTGGGGCGCCGGCCTGCTGAAGCCCAGCGAGACCCTGAGCCTG
ACCTGCGCCGTGTACGGCGGCAGCTTCAGCGGCTACTACTGGAGCTGGATCAGGCAGCCC
CCCGGCAAGGGCCTGGAGTGGATCGGCGAGATCAACCACAGCGGCAGCACCAACTACAAC
CCCAGCCTGAAGAGCAGGGTGACCATCAGCGTGGACACCAGCAAGAACCAGTTCAGCCTG
AAGCTGAGCAGCGTGACCGCCGCCGACACCGCCGTGTACTACTGCGCCAGGGGCTACTAC
GACATCCTGACCGGCTACTACTACTACTTCGACTACTGGGGCCAGGGCACCCTGGTGACC
GTGAGCAGC
>P00483_C02 tanezumab
CAGGTGCAGCTGCAGGAGAGCGGCCCCGGCCTGGTGAAGCCCAGCGAGACCCTGAGCCTG
ACCTGCACCGTGAGCGGCTTCAGCCTGATCGGCTACGACCTGAACTGGATCAGGCAGCCC
CCCGGCAAGGGCCTGGAGTGGATCGGCATCATCTGGGGCGACGGCACCACCGACTACAAC
AGCGCCGTGAAGAGCAGGGTGACCATCAGCAAGGACACCAGCAAGAACCAGTTCAGCCTG
AAGCTGAGCAGCGTGACCGCCGCCGACACCGCCGTGTACTACTGCGCCAGGGGCGGCTAC
TGGTACGCCACCAGCTACTACTTCGACTACTGGGGCCAGGGCACCCTGGTGACCGTGAGC
AGC
>P00483_C03 teplizumab
CAGGTGCAGCTGGTGCAGAGCGGCGGCGGCGTGGTGCAGCCCGGCAGGAGCCTGAGGCTG
AGCTGCAAGGCCAGCGGCTACACCTTCACCAGGTACACCATGCACTGGGTGAGGCAGGCC
CCCGGCAAGGGCCTGGAGTGGATCGGCTACATCAACCCCAGCAGGGGCTACACCAACTAC
AACCAGAAGGTGAAGGACAGGTTCACCATCAGCAGGGACAACAGCAAGAACACCGCCTTC
CTGCAGATGGACAGCCTGAGGCCCGAGGACACCGGCGTGTACTTCTGCGCCAGGTACTAC
GACGACCACTACTGCCTGGACTACTGGGGCCAGGGCACCCCCGTGACCGTGAGCAGC
>P00483_C04 tigatuzumab
GAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCTG
AGCTGCGCCGCCAGCGGCTTCACCTTCAGCAGCTACGTGATGAGCTGGGTGAGGCAGGCC
CCCGGCAAGGGCCTGGAGTGGGTGGCCACCATCAGCAGCGGCGGCAGCTACACCTACTAC
CCCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACGCCAAGAACACCCTGTAC
CTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAGGAGGGGC
GACAGCATGATCACCACCGACTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
>P00483_C05 tildrakizumab
CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCGCCAGCGTGAAGGTG
AGCTGCAAGGCCAGCGGCTACATCTTCATCACCTACTGGATGACCTGGGTGAGGCAGGCC
CCCGGCCAGGGCCTGGAGTGGATGGGCCAGATCTTCCCCGCCAGCGGCAGCGCCGACTAC
AACGAGAAGTTCGAGGGCAGGGTGACCATGACCACCGACACCAGCACCAGCACCGCCTAC
ATGGAGCTGAGGAGCCTGAGGAGCGACGACACCGCCGTGTACTACTGCGCCAGGGGCGGC
GGCGGCTTCGCCTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
>P00483_C06 tocilizumab
CAGGTGCAGCTGCAGGAGAGCGGCCCCGGCCTGGTGAGGCCCAGCCAGACCCTGAGCCTG
ACCTGCACCGTGAGCGGCTACAGCATCACCAGCGACCACGCCTGGAGCTGGGTGAGGCAG
CCCCCCGGCAGGGGCCTGGAGTGGATCGGCTACATCAGCTACAGCGGCATCACCACCTAC
AACCCCAGCCTGAAGAGCAGGGTGACCATGCTGAGGGACACCAGCAAGAACCAGTTCAGC
CTGAGGCTGAGCAGCGTGACCGCCGCCGACACCGCCGTGTACTACTGCGCCAGGAGCCTG
GCCAGGACCACCGCCATGGACTACTGGGGCCAGGGCAGCCTGGTGACCGTGAGCAGC
>P00483_C07 tovetumab
CAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGAAGCCCGGCGGCAGCCTGAGGCTG
AGCTGCGCCGCCAGCGGCTTCACCTTCAGCGACTACTACATGAACTGGATCAGGCAGGCC
CCCGGCAAGGGCCTGGAGTGGGTGAGCTACATCAGCAGCAGCGGCAGCATCATCTACTAC
GCCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACGCCAAGAACAGCCTGTAC
CTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAGGGAGGGC
AGGATCGCCGCCAGGGGCATGGACGTGTGGGGCCAGGGCACCACCGTGACCGTGAGCAGC
>P00483_C08 tralokinumab
CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCGCCAGCGTGAAGGTG
AGCTGCAAGGCCAGCGGCTACACCTTCACCAACTACGGCCTGAGCTGGGTGAGGCAGGCC
CCCGGCCAGGGCCTGGAGTGGATGGGCTGGATCAGCGCCAACAACGGCGACACCAACTAC
GGCCAGGAGTTCCAGGGCAGGGTGACCATGACCACCGACACCAGCACCAGCACCGCCTAC
ATGGAGCTGAGGAGCCTGAGGAGCGACGACACCGCCGTGTACTACTGCGCCAGGGACAGC
AGCAGCAGCTGGGCCAGGTGGTTCTTCGACCTGTGGGGCAGGGGCACCCTGGTGACCGTG
AGCAGC
>P00483_C09 trastuzumab
GAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCTG
AGCTGCGCCGCCAGCGGCTTCAACATCAAGGACACCTACATCCACTGGGTGAGGCAGGCC
CCCGGCAAGGGCCTGGAGTGGGTGGCCAGGATCTACCCCACCAACGGCTACACCAGGTAC
GCCGACAGCGTGAAGGGCAGGTTCACCATCAGCGCCGACACCAGCAAGAACACCGCCTAC
CTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCAGCAGGTGGGGC
GGCGACGGCTTCTACGCCATGGACTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
>P00483_C10 tremelimumab
CAGGTGCAGCTGGTGGAGAGCGGCGGCGGCGTGGTGCAGCCCGGCAGGAGCCTGAGGCTG
AGCTGCGCCGCCAGCGGCTTCACCTTCAGCAGCTACGGCATGCACTGGGTGAGGCAGGCC
CCCGGCAAGGGCCTGGAGTGGGTGGCCGTGATCTGGTACGACGGCAGCAACAAGTACTAC
GCCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACAGCAAGAACACCCTGTAC
CTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAGGGACCCC
AGGGGCGCCACCCTGTACTACTACTACTACGGCATGGACGTGTGGGGCCAGGGCACCACC
GTGACCGTGAGCAGC
>P00483_C11 urelumab
CAGGTGCAGCTGCAGCAGTGGGGCGCCGGCCTGCTGAAGCCCAGCGAGACCCTGAGCCTG
ACCTGCGCCGTGTACGGCGGCAGCTTCAGCGGCTACTACTGGAGCTGGATCAGGCAGAGC
CCCGAGAAGGGCCTGGAGTGGATCGGCGAGATCAACCACGGCGGCTACGTGACCTACAAC
CCCAGCCTGGAGAGCAGGGTGACCATCAGCGTGGACACCAGCAAGAACCAGTTCAGCCTG
AAGCTGAGCAGCGTGACCGCCGCCGACACCGCCGTGTACTACTGCGCCAGGGACTACGGC
CCCGGCAACTACGACTGGTACTTCGACCTGTGGGGCAGGGGCACCCTGGTGACCGTGAGC
AGC
>P00483_C12 ustekinumab
GAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCGAGAGCCTGAAGATC
AGCTGCAAGGGCAGCGGCTACAGCTTCACCACCTACTGGCTGGGCTGGGTGAGGCAGATG
CCCGGCAAGGGCCTGGACTGGATCGGCATCATGAGCCCCGTGGACAGCGACATCAGGTAC
AGCCCCAGCTTCCAGGGCCAGGTGACCATGAGCGTGGACAAGAGCATCACCACCGCCTAC
CTGCAGTGGAACAGCCTGAAGGCCAGCGACACCGCCATGTACTACTGCGCCAGGAGGAGG
CCCGGCCAGGGCTACTTCGACTTCTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
>P00483_D01 vedolizumab
CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCGCCAGCGTGAAGGTG
AGCTGCAAGGGCAGCGGCTACACCTTCACCAGCTACTGGATGCACTGGGTGAGGCAGGCC
CCCGGCCAGAGGCTGGAGTGGATCGGCGAGATCGACCCCAGCGAGAGCAACACCAACTAC
AACCAGAAGTTCAAGGGCAGGGTGACCCTGACCGTGGACATCAGCGCCAGCACCGCCTAC
ATGGAGCTGAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTACTGCGCCAGGGGCGGC
TACGACGGCTGGGACTACGCCATCGACTACTGGGGCCAGGGCACCCTGGTGACCGTGAGC
AGC
>P00483_D02 veltuzumab
CAGGTGCAGCTGCAGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCAGCAGCGTGAAGGTG
AGCTGCAAGGCCAGCGGCTACACCTTCACCAGCTACAACATGCACTGGGTGAAGCAGGCC
CCCGGCCAGGGCCTGGAGTGGATCGGCGCCATCTACCCCGGCATGGGCGACACCAGCTAC
AACCAGAAGTTCAAGGGCAAGGCCACCCTGACCGCCGACGAGAGCACCAACACCGCCTAC
ATGGAGCTGAGCAGCCTGAGGAGCGAGGACACCGCCTTCTACTACTGCGCCAGGAGCACC
TACTACGGCGGCGACTGGTACTTCGACGTGTGGGGCCAGGGCACCACCGTGACCGTGAGC
AGC
>P00483_D03 visilizumab
CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCGCCAGCGTGAAGGTG
AGCTGCAAGGCCAGCGGCTACACCTTCATCAGCTACACCATGCACTGGGTGAGGCAGGCC
CCCGGCCAGGGCCTGGAGTGGATGGGCTACATCAACCCCAGGAGCGGCTACACCCACTAC
AACCAGAAGCTGAAGGACAAGGCCACCCTGACCGCCGACAAGAGCGCCAGCACCGCCTAC
ATGGAGCTGAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTACTGCGCCAGGAGCGCC
TACTACGACTACGACGGCTTCGCCTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
>P00483_D04 zalutumumab
CAGGTGCAGCTGGTGGAGAGCGGCGGCGGCGTGGTGCAGCCCGGCAGGAGCCTGAGGCTG
AGCTGCGCCGCCAGCGGCTTCACCTTCAGCACCTACGGCATGCACTGGGTGAGGCAGGCC
CCCGGCAAGGGCCTGGAGTGGGTGGCCGTGATCTGGGACGACGGCAGCTACAAGTACTAC
GGCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACAGCAAGAACACCCTGTAC
CTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAGGGACGGC
ATCACCATGGTGAGGGGCGTGATGAAGGACTACTTCGACTACTGGGGCCAGGGCACCCTG
GTGACCGTGAGCAGC
>P00483_D05 zanolimumab
CAGGTGCAGCTGCAGCAGTGGGGCGCCGGCCTGCTGAAGCCCAGCGAGACCCTGAGCCTG
ACCTGCGCCGTGTACGGCGGCAGCTTCAGCGGCTACTACTGGAGCTGGATCAGGCAGCCC
CCCGGCAAGGGCCTGGAGTGGATCGGCGAGATCAACCACAGCGGCAGCACCAACTACAAC
CCCAGCCTGAAGAGCAGGGTGACCATCAGCGTGGACACCAGCAAGAACCAGTTCAGCCTG
AAGCTGAGCAGCGTGACCGCCGCCGACACCGCCGTGTACTACTGCGCCAGGGTGATCAAC
TGGTTCGACCCCTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC